Company: APM
Filing Date: 2025-10-06
Form Type: S-4
Source: 0001213900-25-096656
Chunk: 3

Company: Aptorum Group Ltd
Filing Date: 2025-10-06
Form: S-4
Chunk 3
---
R LLC, a wholly owned subsidiary of DiamiR, and Aptorum Therapeutics entered into that certain Limited Interim Patent and Know -HowLicense Agreement (the “Intellectual Property License Agreement”), pursuant to which DiamiR and DiamiR LLC shall license on a non -exclusivebasis their respective intellectual properties to the Company in exchange for an upfront payment equal to $5,000, and monthly payments in the amount of $1,200 until the earlier of the closing of the Merger or December31, 2025. Immediately prior to the closing of Merger, Aptorum will transfer by way of continuation to and domesticate as a Delaware corporation (the “Domestication”; the Company immediately following the Domestication and prior to the closing of Merger, “Aptorum Delaware”). In connection with the Domestication, each then issued and outstanding Class A ordinary share of Aptorum will convert automatically, on a one -for-onebasis, into a share of common stock of Aptorum Delaware, each then issued and outstanding Class B ordinary share of Aptorum will convert automatically into a share of common stock of Aptorum Delaware and a share of non -votingand non -convertibleSeries A preferred stock of Aptorum Delaware. If the issuance were to occur on October3, 2025, a total of 10,071,034shares of Aptorum Delaware’s common stock and 1,796,934shares of non -convertibleSeries A preferred stock, respectively, would be issued to Aptorum’s existing shareholders. At the effective time of the Merger (the “Effective Time” or the “Closing”), each then -outstandingshare of DiamiR’s common stock, other than dissenting shares, will be converted into a number of shares of Aptorum Delaware common stock equal to the Conversion Ratio, which is the number resulting from dividing (i) the quotient of dividing the total number of Aptorum ordinary shares on a fully diluted basis by the total number of shares of DiamiR common stock on a fully diluted basis, by (ii) three -seventh(3/7), as described in more detail in the section titled “The Merger Agreement -ConversionRatio” (the “Conversion Ratio”). If the issuance were to occur on October3, 2025, a total of 23,499,080shares of Aptorum Delaware’s common stock would be issued to current stockholders of DiamiR and no shares of Series A preferred stock will be issued to any current Diami